Latest news with #RegulusTherapeuticsInc
San Francisco Chronicle
08-05-2025
- Business
- San Francisco Chronicle
Regulus: Q1 Earnings Snapshot
SAN DIEGO (AP) — SAN DIEGO (AP) — Regulus Therapeutics Inc. (RGLS) on Thursday reported a loss of $9.6 million in its first quarter. The San Diego-based company said it had a loss of 15 cents per share. The results exceeded Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was for a loss of 29 cents per share.
Globe and Mail
30-04-2025
- Business
- Globe and Mail
Biotech Stock Soars Over 100% On Premarket Following Acquisition Announcement
A California-based biotech company is absolutely stealing the spotlight after it was announced that Novartis AG is set to acquire it. The press release mentions that Novartis is to acquire the company 'for $7.00 per share in cash, with potential to receive an additional $7.00 per share in cash through a contingent value right, for a total equity value of up to approximately $1.7 billion.' Seeing that Regulus Therapeutics Inc. (Nasdaq:RGLS) closed at just $3.37 on Tuesday, it's no wonder that shares of this small cap are already off to the races, with traders currently bid at $7.82/share (132.05% implied open for sellers). Be sure to keep your eye on this one! Regulus Therapeutics Inc is a biotechnology company focused on the development of microRNA therapies. MicroRNA therapies target diseases such as cancer, metabolic diseases, fibrosis, and inflammatory diseases. MicroRNA is a noncoding ribonucleic acid that regulates most genes in the genome. The company partnered with Sanofi to create a compound targeting orphan diseases and with AstraZeneca to cure Type 2 Diabetes/prediabetes. Copyright © 2025 All rights reserved. Republication or redistribution of content is expressly prohibited without the prior written consent of shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. View more of this article on About Media, Inc.: Founded in 1999, is one of North America's leading platforms for micro-cap insights. Catering to both Canadian and U.S. markets, we provide a wealth of resources and expert content designed for everyone—from beginner investors to seasoned traders. is rapidly gaining recognition as a leading authority in the micro-cap space, with our insightful content prominently featured across numerous top-tier financial platforms, reaching a broad audience of investors and industry professionals. Want to showcase your company's story to a powerful network of investors? We can help you elevate your message and make a lasting impact. Contact us today. Contact: Media, Inc.
Bloomberg
30-04-2025
- Business
- Bloomberg
Novartis to Buy Regulus Therapeutics for as Much as $1.7 Billion
Novartis AG agreed to buy US biotech Regulus Therapeutics Inc. in a deal that could be valued at up to $1.7 billion. The Swiss company will pay $7 a share in cash upfront through a subsidiary, equivalent to $800 million, according to a statement Wednesday.
Yahoo
20-04-2025
- Business
- Yahoo
Is Regulus Therapeutics Inc. (RGLS) the Best Rising Penny Stock to Buy According to Analysts?
We recently published a list of the . In this article, we are going to take a look at where Regulus Therapeutics Inc. (NASDAQ:RGLS) stands against other best rising penny stocks to buy according to analysts. The start of 2025 was characterized by a series of challenges for the US equities across the board. Tariffs, inflationary concerns, the risk of recession, and loss of consumer confidence, all led to the small-cap Russell 2000 Index falling 9.5% and the large-cap Russell 1000 Index falling 4.5%. On April 1, Royce Investment released its fiscal first quarter outlook for small-cap stocks. Francis Gannon, who is the Co-Chief Investment Officer, and Managing Director, noted that while the large-cap outperformed the small-caps, however, this performance was not concentrated among the Magnificent Seven, which has dominated the market previously. This is evident from the fact that the Russell Top 50 Index fell 7.6%, whereas the NASDAQ Composite was down more than 10.3%. Gannon highlighted that while the small-cap stocks underperformed the large caps, however, the divergence from the Mag Seven is a positive trend for the small-cap stocks. He noted that historically speaking the broadening of the market away from the top few stocks has meant good things for the small caps in the long term. Moreover, while dissecting the performance of small-cap equities during the downturn, Gannon noted that the Russell 2000 Value Index held better as compared to the Russell 2000 Growth Index. The small-cap value stocks have outperformed the growth counterparts over 1 and 5-year comparisons. However, when looked up from a 10-year standpoint the performance for both categories remains the same. Gannon further pointed out that during the first quarter of 2025, the biggest detractors of the Index were Information Technology, Industrials, Health Care, and Consumer Discretionary, while Utilities was the only positive contributor. Lasty, Gannon shared his experience of being a small-cap investment strategist for over 50 years. He highlighted it is still too early to tell if the first quarter drop for small-cap stocks was only short-term or indicates a long-term period of falling, however, he noted that corrections are common for the small-cap investors. Gannon advised investors to learn to be greedy when others are fearful and vice versa if they are interested in small caps. Moreover, looking at the stocks from a valuation standpoint, small caps remain largely undervalued as compared to large caps and Gannon advised the key to tackling periods of uncertainty is to remain invested. To compile the list of the 10 best-rising penny stocks to buy according to analysts, we used the Finviz stock screener and CNN. Using the screener, we aggregated the list of penny stocks (trading between $1 and $5) with more than 30% share price appreciation over the past month, and more than 30% average upside potential. Lastly, we sorted the list by market capitalization and ranked the stocks in ascending order of the number of hedge funds sourced from Insider Monkey's Q4 2024 database. Please note that the data was collected on April 17, 2025. Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter's strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (). A factory worker in a hard hat operating a machine, symbolizing the preclinical drug production process. Regulus Therapeutics Inc. (NASDAQ:RGLS) is another clinical-stage pharmaceutical company that engages in the development of medicines that target microRNAs to treat various unmet medical conditions. Its key focus area includes Orphan Kidney Disease with Farabursen being its main drug candidate. On March 31, Leerink Partners analyst Joseph Schwartz reiterated a Buy rating on Regulus Therapeutics Inc. (NASDAQ:RGLS). The analyst noted that the company's lead drug candidate for treating ADPKD showed positive results in the fourth cohort of the phase 1b study. The results indicate that the drug is effective in curbing the growth of height-adjusted total kidney volume. Moreover, Schwartz also likes the company's engagement with the FDA which topped with the positive results points towards speedy approvals. Considering these positive factors, analysts anticipate more than 284% upside for the stock, making it the best-rising penny stock to buy according to analysts. Overall, RGLS ranks 1st on our list of best rising penny stocks to buy according to analysts. While we acknowledge the potential of RGLS to grow, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. There is an AI stock that went up since the beginning of 2025, while popular AI stocks lost around 25%. If you are looking for an AI stock that is more promising than RGLS but that trades at less than 5 times its earnings, check out our report about the . READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey.
